VistaGen To Report Phase 3 Data From Social Anxiety Disorder Trial In Mid-2022

(RTTNews) - VistaGen Therapeutics Inc. (VTGN) has a couple of clinical trial catalysts over the next 6 to 12 months.

The company's lead product candidate is PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder, under a phase III program, dubbed PALISADE.

The first U.S. phase III clinical study of PH94B, under the PALISADE program, dubbed PALISADE-1, is underway. The topline data from the PALISADE-1 trial is anticipated in mid-2022. The second U.S. phase III study of PH94B, under the PALISADE program, dubbed PALISADE-2, is expected to be initiated in the second half of 2021.

Next up in the pipeline is PH10 for Major Depressive Disorder (MDD), which has completed a phase IIa trial. The company expects to initiate a phase IIb trial to evaluate the efficacy and safety of PH10 as a potential stand-alone treatment for MDD in mid-2022.

Yet another MDD drug being developed by the company is AV-101. A phase IB clinical study evaluating AV-101 in combination with probenecid is expected to be initiated in the second half of 2021.

At March 31, 2021, the company had cash and cash equivalents of approximately $103.1 million.

VTGN closed Tuesday's trading at $2.68, down 5.63%.